On our screens:R&D leaders
Is the price fair?
What ALNY's price assumes
Alnylam Pharmaceuticals, Inc. trades at 132× earnings against 31.5× for the median Biotechnology name, more expensive than its own group.
132
Trailing P/E · Biotechnology median 31.5 · 4.19× the median: the market pays up for this one
- Price / sales
- 14.2
Price / sales · as of 2025-Q4
- Free cash flow yield
- 1.2%
Free cash flow yield · Biotechnology median 2.4%
- Growth the price implies
- +25%
Growth the price implies · The price pays for +25% free cash flow growth a year for a decade; revenue has grown +53% a year over the last three.
Details›
- Price / book2025-Q4
- 66.7
- Healthcare median P/E362 names
- 29.9
- Biotechnology median P/E158 names
- 31.5
- Free cash flow, trailing twelve months
- $465M
- Market capitalisation
- $39.1B
- 3-year revenue growth
- +53%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Biotechnology
Ranks #89 of 143 by Smart Score